Urinary Peptide Signatures Distinguish Overactive Bladder and are Associated with Improvement in Incontinence Following Therapy.
Urinary peptide testing distinguishes overactive bladder from healthy controls with good accuracy.
Urinary Peptide Signatures Distinguish Overactive Bladder and are Associated with Improvement in Incontinence Following Therapy.
To characterize urinary peptide signatures in patients with and without overactive bladder (overactive bladder), identify peptide differences by overactive bladder phenotype, and determine the association between baseline peptide profiles and improvement in incontinence following therapy.
Completed validated questionnaires at baseline and following treatment.
peptide testing accurately separated overactive bladder from controls, above chance
The urinary peptidome differed significantly between patients with overactive bladder and controls in overall peptide composition (p=0.001) and number of unique peptides (p=0.001).
Peptides from fibrillin-1 and quiescin sulfhydryl oxidase 1 were more abundant in overactive bladder.
Baseline peptide composition differed between those who experienced improvement in incontinence versus those who did not experience improvement following therapy in the overall cohort (p=0.03) and sacral neuromodulation group (p=0.04).
Overactive bladder is associated with a unique urinary peptide signature that reflects extracellular matrix remodeling, oxidative stress, and altered cellular metabolism.
Baseline peptide profiles differ between those who symptomatically improved versus did not improve following therapy suggesting potential utility of urinary peptides as prognostic biomarkers.
These findings support the heterogeneous nature of overactive bladder pathophysiology and may facilitate development of new diagnostic and personalized therapeutic approaches.